Gilead Sciences, Inc.
GILDGilead Sciences, Inc. (/ˈɡɪliəd/) is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Drugs in Pipeline
200
Phase 3 Programs
107
Upcoming Catalysts
9
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
13 upcoming, 4 past
Trodelvy
Sacituzumab Govitecan
Triple-Negative Breast Cancer
MTX
Rheumatoid Arthritis
ABC/3TC
HIV-1 Infection
Elvitegravir
HIV Infection
GS-4182
HIV-1-Infection
F/R/TAF
HIV-1 Infection
Stable Baseline Regimen
HIV-1-infection
Seladelpar 5 mg Capsule
Primary Biliary Cirrhosis
Remdesivir
COVID-19
Zidovudine
HIV Infections
Adefovir Dipivoxil for oral suspension, 2 mg/mL
Chronic Hepatitis B
Platinum-containing Salvage Chemotherapy
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Tobramycin inhalation solution
Cystic Fibrosis
Lenacapavir Tablet
HIV Pre-exposure Prophylaxis
F/TAF
HIV-1 Infection
EVG/COBI/FTC/TDF
Acquired Immunodeficiency Syndrome
EFV/FTC/TDF
HIV
Subcutaneous Lenacapavir
HIV-1-infection
AZLI 75 mg three times a day (TID)
Cystic Fibrosis
NRTIs
HIV-1 Infection
TAF
HBeAg-positive Chronic Hepatitis B
RBV
Hepatitis C Virus Infection
Atripla
HIV
COBI
Acquired Immunodeficiency Syndrome
Adenosine
Coronary Artery Disease
Tenofovir disoproxil fumarate
Chronic Hepatitis B
Tobramycin Inhalation Solution (TIS)
Cystic Fibrosis
PTM B/F/TAF
HIV-1-infection
B/F/TAF (Adult Strength)
HIV-1 Infection
FTC/RPV/TDF
HIV-1 Infection
E/C/F/TAF
HIV
Tenofovir disoproxil fumarate (TDF)
Hepatitis B Virus (HBV)
SOF
Hepatitis C
BIC/LEN FDC
HIV-1-infection
FTC/TDF
Chronic Hepatitis B
Oral Lenacapavir
HIV-1-infection
Ranolazine
Type 2 Diabetes Mellitus
AZLI
Cystic Fibrosis
Tenofovir DF
HIV Infections
B/F/TAF
HIV-1-infection
F/TDF
Pre-Exposure Prophylaxis of HIV-1 Infection
MBX-102
Type 2 Diabetes
Filgotinib
Ulcerative Colitis
Aztreonam for Inhalation Solution (AZLI)
Cystic Fibrosis
Idelalisib
Hodgkin Lymphoma
SOF/VEL
Hepatitis C Virus Infection
Sacituzumab govitecan-hziy (SG)
Triple Negative Breast Cancer
Peg-IFN
Hepatitis C
Sacituzumab Govitecan-hziy
Triple Negative Breast Cancer
csDMARDs
Rheumatoid Arthritis
ADV
Chronic Hepatitis B
Lenacapavir Injection
Pre-Exposure Prophylaxis of HIV Infection
AmBisome
Invasive Aspergillosis
DTG
HIV-1/HBV Co-Infection
Anitocabtagene Autoleucel
Multiple Myeloma
Liposomal amphotericin B
Invasive Fungal Disease
Andecaliximab
Gastric Adenocarcinoma
Domvanalimab
Advanced Non-Small Cell Lung Cancer
Eribulin
Metastatic Breast Cancer
E/C/F/TDF
HIV
PI
HIV-1 Infection
TDF
Chronic Hepatitis B
LDV/SOF
Chronic Hepatitis C Virus
ambrisentan
Pulmonary Hypertension
Optimized Background Regimen (OBR)
HIV-1-infection
Eribulin Mesylate Injection
Metastatic Breast Cancer
Viread (tenofovir disoproxil fumarate)
HIV Infections
KITE-753
Relapsed or Refractory Large B-cell Lymphoma
GS-1720
HIV-1-infection
AZLI 75 mg two times a day (BID)/three times a day (TID)
Cystic Fibrosis
AZLI 75 mg two times a day (BID)/ three times a day (TID)
Cystic Fibrosis
Cobicistat
Acquired Immune Deficiency Syndrome (AIDS)
SOF/VEL/VOX
Hepatitis C Virus Infection
NNRTI
Acquired Immunodeficiency Syndrome
Obeldesivir
COVID-19
PEG
Hepatitis C
Bictegravir
HIV-1-infection
Sofosbuvir
Hepatitis C, Chronic
E/C/F/TAF (Low Dose)
Acquired Immune Deficiency Syndrome (AIDS)
ISL/LEN
HIV-1-Infection
Bulevirtide
Chronic Hepatitis Delta
Darusentan
Hypertension
FTC
Chronic Hepatitis B
Seladelpar 10 mg
Primary Biliary Cholangitis
3rd ARV agent
HIV-1
Emtricitabine (FTC)
HIV Infections
DRV
HIV-1 Infection
Regadenoson
Coronary Artery Disease
ATV
HIV
FTC/RPV/TAF
HIV-1 Infection
Vinflunine
Locally Advanced or Metastatic Unresectable Urothelial Cancer
AZLI 75 mg three times daily (TID)
Cystic Fibrosis
3TC
HIV-1 Infection
zidovudine and lamivudine (Combivir®)
HIV Infections
Subcutaneous (SC) Lenacapavir (LEN)
Pre-Exposure Prophylaxis of HIV Infection
Lenacapavir
HIV Prevention
Magrolimab
Myelodysplastic Syndrome
Zimberelimab
Head and Neck Squamous Cell Carcinoma
Stribild
Acquired Immunodeficiency Syndrome
Sacituzumab Govitecan (SG)
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Baseline DRV- containing ARV regimen
HIV-1
seladelpar 5-10 mg
Primary Biliary Cholangitis
RTV
Acquired Immunodeficiency Syndrome
Seladelpar
Primary Biliary Cholangitis
Current failing ARV regimen
HIV
Adefovir Dipivoxil (ADV)
Chronic Hepatitis B
ABC/DTG/3TC
HIV-1 Infection
Axicabtagene Ciloleucel
High-risk Large B-cell Lymphoma (LBCL)
Hepatitis B virus (HBV) OAV Therapy
Chronic Hepatitis B
BSF 208075
Pulmonary Hypertension
Cidofovir
Cytomegalovirus Retinitis
GS-9451
Hepatitis C, Chronic
KTE-C19
Refractory Diffuse Large B Cell Lymphoma
Febuxostat
Gout
Remdesivir (RDV)
COVID-19
D/C/F/TAF
Acquired Immunodeficiency Syndrome
GS-9876
Rheumatoid Arthritis
Avelumab
Metastatic Urothelial Cancer
Efavirenz
HIV Infections
Tegobuvir (GS-9190)
Hepatitis C, Chronic
radiolabeled epratuzumab
Non-Hodgkin's Lymphoma
Nelfinavir mesylate
HIV Infections
emtricitabine /tenofovir DF
Chronic Hepatitis B
IMMU-107 (hPAM4)
Pancreatic Cancer
Tenofovir disoproxil fumarate (tenofovir DF; TDF)
Chronic Hepatitis B
BIC
HIV-1 Infection
FIR
Nonalcoholic Steatohepatitis
Hepatitis B Immunoglobulin (HBIg)
Chronic Hepatitis B
Adefovir Dipivoxil
Hepatitis B
ISL
HIV-1 Infection
MBX-8025
Hyperlipidemia
Arhalofenate
Hyperuricemia
brexucabtagene autoleucel
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
veltuzumab
NHL
Tenofovir Alafenamide
Chronic Hepatitis B
Abacavir
HIV
GS-9137 - A Novel HIV-1 Integrase Inhibitor
HIV
VOX
Hepatitis C Virus Infection
SIM
Non-Alcoholic Steatohepatitis (NASH)
Aztreonam for Inhalation (AI)
Cystic Fibrosis
Tilpisertib Fosmecarbil
Ulcerative Colitis
Dronedarone
Atrial Fibrillation
tegobuvir capsule
Chronic Genotype 1a or 1b HCV Infection
anitocabtagene-autoleucel
Multiple Myeloma
KTE-X19
Relapsed/Refractory Mantle Cell Lymphoma
SEL
Diabetic Kidney Disease
MBX-2982
Diabetes
CILO
Nonalcoholic Steatohepatitis (NASH)
Pegasys®
Chronic Hepatitis C Infection
Levetiracetam
Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Denikitug
HER2-negative
KITE-363
Relapsed and/or Refractory B-cell Lymphoma
VDV
Hepatitis C Virus Infection
Simtuzumab
Primary Sclerosing Cholangitis (PSC)
FTI, AZLI
Cystic Fibrosis
Tecadenoson
Atrial Fibrillation
OAV Regimen
Chronic HBV Infection
EFV
Hepatitis C
milatuzumab
Chronic Lymphocytic Lymphoma
Emtricitabine
HIV Infections
abacavir 300mg twice daily
Lipodystrophy
Tegobuvir
Hepatitis C, Chronic
GS-9190
HCV Infection
Brexucabtagene Autoleucel (KTE-X19)
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
MBX-8025 2 mg Capsule
Primary Biliary Cirrhosis
GS-9450
Nonalcoholic Steatohepatitis
hA20-humanized anti-CD20 antibody
Non-Hodgkin's Lymphoma
LDV
Chronic Hepatitis C Infection
GS-1427
Ulcerative Colitis
GS-5806
Respiratory Syncytial Virus Infections
Eleclazine
Ventricular Arrhythmia
GS-5885
Hepatitis C, Chronic
90Y-hLL2
NHL
Vesatolimod
HIV-1-infection
Other approved antivirals
Chronic Hepatitis B
Cilofexor
Primary Sclerosing Cholangitis
GS-5885 tablet
Hepatitis C, Chronic
Selonsertib
Alcoholic Hepatitis (AH)
VEL
Hepatitis C
Teropavimab
HIV Infection
hMN14 (labetuzumab)
Pancreatic Neoplasms
EVG
HIV Infections
Abacavir sulfate
HIV Infections
Firsocostat
Nonalcoholic Steatohepatitis (NASH)
GS-9674
Nonalcoholic Steatohepatitis (NASH)
Lanraplenib
Lupus Membranous Nephropathy
Presatovir
Respiratory Syncytial Virus
Selgantolimod
Chronic Hepatitis B
GS-9669
Chronic HCV Infection
Zimberelimab (ZIM)
Lung Cancer
Arhalofenate 600 mg
Gout
GS-9256
HCV Infection
MBX-2044
Type 2 Diabetes Mellitus
MBX-8025 50 mg (Dose Escalation Period 1)
Homozygous Familial Hypercholesterolemia
Tirabrutinib
Chronic Lymphocytic Leukemia
Emtricitabine/tenofovir disoproxil fumarate (F/TDF)
Pre-Exposure Prophylaxis of HIV Infection
Indinavir sulfate
HIV Infections
GS-4321
Chronic Hepatitis Delta
90Y-hPAM4
Pancreatic Cancer
Edecesertib
Cutaneous Lupus Erythematosus (CLE)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trodelvy Sacituzumab Govitecan | Approved | Triple-Negative Breast Cancer | Fast TrackBreakthrough | - |
MTX | Phase 3 | Rheumatoid Arthritis | - | - |
ABC/3TC | Phase 3 | HIV-1 Infection | - | - |
Elvitegravir | Phase 3 | HIV Infection | - | - |
GS-4182 | Phase 3 | HIV-1-Infection | - | - |
F/R/TAF | Phase 3 | HIV-1 Infection | - | - |
Stable Baseline Regimen | Phase 3 | HIV-1-infection | - | - |
Seladelpar 5 mg Capsule | Phase 3 | Primary Biliary Cirrhosis | - | - |
Remdesivir | Phase 3 | COVID-19 | - | - |
Zidovudine | Phase 3 | HIV Infections | - | - |
Adefovir Dipivoxil for oral suspension, 2 mg/mL | Phase 3 | Chronic Hepatitis B | - | - |
Platinum-containing Salvage Chemotherapy | Phase 3 | Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | - | - |
Tobramycin inhalation solution | Phase 3 | Cystic Fibrosis | - | - |
Lenacapavir Tablet | Phase 3 | HIV Pre-exposure Prophylaxis | - | - |
F/TAF | Phase 3 | HIV-1 Infection | - | - |
EVG/COBI/FTC/TDF | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
EFV/FTC/TDF | Phase 3 | HIV | - | - |
Subcutaneous Lenacapavir | Phase 3 | HIV-1-infection | - | - |
AZLI 75 mg three times a day (TID) | Phase 3 | Cystic Fibrosis | - | - |
NRTIs | Phase 3 | HIV-1 Infection | - | - |
TAF | Phase 3 | HBeAg-positive Chronic Hepatitis B | - | - |
RBV | Phase 3 | Hepatitis C Virus Infection | - | - |
Atripla | Phase 3 | HIV | - | - |
COBI | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Adenosine | Phase 3 | Coronary Artery Disease | - | - |
Tenofovir disoproxil fumarate | Phase 3 | Chronic Hepatitis B | - | - |
Tobramycin Inhalation Solution (TIS) | Phase 3 | Cystic Fibrosis | - | - |
PTM B/F/TAF | Phase 3 | HIV-1-infection | - | - |
B/F/TAF (Adult Strength) | Phase 3 | HIV-1 Infection | - | - |
FTC/RPV/TDF | Phase 3 | HIV-1 Infection | - | - |
E/C/F/TAF | Phase 3 | HIV | - | - |
Tenofovir disoproxil fumarate (TDF) | Phase 3 | Hepatitis B Virus (HBV) | - | - |
SOF | Phase 3 | Hepatitis C | - | - |
BIC/LEN FDC | Phase 3 | HIV-1-infection | - | - |
FTC/TDF | Phase 3 | Chronic Hepatitis B | - | - |
Oral Lenacapavir | Phase 3 | HIV-1-infection | - | - |
Ranolazine | Phase 3 | Type 2 Diabetes Mellitus | - | - |
AZLI | Phase 3 | Cystic Fibrosis | - | - |
Tenofovir DF | Phase 3 | HIV Infections | - | - |
B/F/TAF | Phase 3 | HIV-1-infection | - | - |
F/TDF | Phase 3 | Pre-Exposure Prophylaxis of HIV-1 Infection | - | - |
MBX-102 | Phase 3 | Type 2 Diabetes | - | - |
Filgotinib | Phase 3 | Ulcerative Colitis | - | - |
Aztreonam for Inhalation Solution (AZLI) | Phase 3 | Cystic Fibrosis | - | - |
Idelalisib | Phase 3 | Hodgkin Lymphoma | - | - |
SOF/VEL | Phase 3 | Hepatitis C Virus Infection | - | - |
Sacituzumab govitecan-hziy (SG) | Phase 3 | Triple Negative Breast Cancer | - | - |
Peg-IFN | Phase 3 | Hepatitis C | - | - |
Sacituzumab Govitecan-hziy | Phase 3 | Triple Negative Breast Cancer | - | - |
csDMARDs | Phase 3 | Rheumatoid Arthritis | - | - |
ADV | Phase 3 | Chronic Hepatitis B | - | - |
Lenacapavir Injection | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
AmBisome | Phase 3 | Invasive Aspergillosis | - | - |
DTG | Phase 3 | HIV-1/HBV Co-Infection | - | - |
Anitocabtagene Autoleucel | Phase 3 | Multiple Myeloma | - | - |
Liposomal amphotericin B | Phase 3 | Invasive Fungal Disease | - | - |
Andecaliximab | Phase 3 | Gastric Adenocarcinoma | - | - |
Domvanalimab | Phase 3 | Advanced Non-Small Cell Lung Cancer | - | - |
Eribulin | Phase 3 | Metastatic Breast Cancer | - | - |
E/C/F/TDF | Phase 3 | HIV | - | - |
PI | Phase 3 | HIV-1 Infection | - | - |
TDF | Phase 3 | Chronic Hepatitis B | - | - |
LDV/SOF | Phase 3 | Chronic Hepatitis C Virus | - | - |
ambrisentan | Phase 3 | Pulmonary Hypertension | - | - |
Optimized Background Regimen (OBR) | Phase 3 | HIV-1-infection | - | - |
Eribulin Mesylate Injection | Phase 3 | Metastatic Breast Cancer | - | - |
Viread (tenofovir disoproxil fumarate) | Phase 3 | HIV Infections | - | - |
KITE-753 | Phase 3 | Relapsed or Refractory Large B-cell Lymphoma | - | - |
GS-1720 | Phase 3 | HIV-1-infection | - | - |
AZLI 75 mg two times a day (BID)/three times a day (TID) | Phase 3 | Cystic Fibrosis | - | - |
AZLI 75 mg two times a day (BID)/ three times a day (TID) | Phase 3 | Cystic Fibrosis | - | - |
Cobicistat | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
SOF/VEL/VOX | Phase 3 | Hepatitis C Virus Infection | - | - |
NNRTI | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Obeldesivir | Phase 3 | COVID-19 | - | - |
PEG | Phase 3 | Hepatitis C | - | - |
Bictegravir | Phase 3 | HIV-1-infection | - | - |
Sofosbuvir | Phase 3 | Hepatitis C, Chronic | - | - |
E/C/F/TAF (Low Dose) | Phase 3 | Acquired Immune Deficiency Syndrome (AIDS) | - | - |
ISL/LEN | Phase 3 | HIV-1-Infection | - | - |
Bulevirtide | Phase 3 | Chronic Hepatitis Delta | - | - |
Darusentan | Phase 3 | Hypertension | - | - |
FTC | Phase 3 | Chronic Hepatitis B | - | - |
Seladelpar 10 mg | Phase 3 | Primary Biliary Cholangitis | - | - |
3rd ARV agent | Phase 3 | HIV-1 | - | - |
Emtricitabine (FTC) | Phase 3 | HIV Infections | - | - |
DRV | Phase 3 | HIV-1 Infection | - | - |
Regadenoson | Phase 3 | Coronary Artery Disease | - | - |
ATV | Phase 3 | HIV | - | - |
FTC/RPV/TAF | Phase 3 | HIV-1 Infection | - | - |
Vinflunine | Phase 3 | Locally Advanced or Metastatic Unresectable Urothelial Cancer | - | - |
AZLI 75 mg three times daily (TID) | Phase 3 | Cystic Fibrosis | - | - |
3TC | Phase 3 | HIV-1 Infection | - | - |
zidovudine and lamivudine (Combivir®) | Phase 3 | HIV Infections | - | - |
Subcutaneous (SC) Lenacapavir (LEN) | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Lenacapavir | Phase 3 | HIV Prevention | Fast TrackBreakthrough | Patent 2041 |
Magrolimab | Phase 3 | Myelodysplastic Syndrome | OrphanFast TrackBreakthrough | - |
Zimberelimab | Phase 3 | Head and Neck Squamous Cell Carcinoma | - | - |
Stribild | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Sacituzumab Govitecan (SG) | Phase 3 | Extensive Stage Small Cell Lung Cancer (ES-SCLC) | - | - |
Baseline DRV- containing ARV regimen | Phase 3 | HIV-1 | - | - |
seladelpar 5-10 mg | Phase 3 | Primary Biliary Cholangitis | - | - |
RTV | Phase 3 | Acquired Immunodeficiency Syndrome | - | - |
Seladelpar | Phase 3 | Primary Biliary Cholangitis | - | - |
Current failing ARV regimen | Phase 3 | HIV | - | - |
Adefovir Dipivoxil (ADV) | Phase 3 | Chronic Hepatitis B | - | - |
ABC/DTG/3TC | Phase 3 | HIV-1 Infection | - | - |
Axicabtagene Ciloleucel | Phase 3 | High-risk Large B-cell Lymphoma (LBCL) | - | - |
Hepatitis B virus (HBV) OAV Therapy | Phase 2 | Chronic Hepatitis B | - | - |
BSF 208075 | Phase 2 | Pulmonary Hypertension | - | - |
Cidofovir | Phase 2 | Cytomegalovirus Retinitis | - | - |
GS-9451 | Phase 2 | Hepatitis C, Chronic | - | - |
KTE-C19 | Phase 2 | Refractory Diffuse Large B Cell Lymphoma | - | - |
Febuxostat | Phase 2 | Gout | - | - |
Remdesivir (RDV) | Phase 2 | COVID-19 | - | - |
D/C/F/TAF | Phase 2 | Acquired Immunodeficiency Syndrome | - | - |
GS-9876 | Phase 2 | Rheumatoid Arthritis | - | - |
Avelumab | Phase 2 | Metastatic Urothelial Cancer | - | - |
Efavirenz | Phase 2 | HIV Infections | - | - |
Tegobuvir (GS-9190) | Phase 2 | Hepatitis C, Chronic | - | - |
radiolabeled epratuzumab | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
Nelfinavir mesylate | Phase 2 | HIV Infections | - | - |
emtricitabine /tenofovir DF | Phase 2 | Chronic Hepatitis B | - | - |
IMMU-107 (hPAM4) | Phase 2 | Pancreatic Cancer | - | - |
Tenofovir disoproxil fumarate (tenofovir DF; TDF) | Phase 2 | Chronic Hepatitis B | - | - |
BIC | Phase 2 | HIV-1 Infection | - | - |
FIR | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
Hepatitis B Immunoglobulin (HBIg) | Phase 2 | Chronic Hepatitis B | - | - |
Adefovir Dipivoxil | Phase 2 | Hepatitis B | - | - |
ISL | Phase 2 | HIV-1 Infection | - | - |
MBX-8025 | Phase 2 | Hyperlipidemia | - | - |
Arhalofenate | Phase 2 | Hyperuricemia | - | - |
brexucabtagene autoleucel | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - | - |
veltuzumab | Phase 2 | NHL | - | - |
Tenofovir Alafenamide | Phase 2 | Chronic Hepatitis B | - | - |
Abacavir | Phase 2 | HIV | - | - |
GS-9137 - A Novel HIV-1 Integrase Inhibitor | Phase 2 | HIV | - | - |
VOX | Phase 2 | Hepatitis C Virus Infection | - | - |
SIM | Phase 2 | Non-Alcoholic Steatohepatitis (NASH) | - | - |
Aztreonam for Inhalation (AI) | Phase 2 | Cystic Fibrosis | - | - |
Tilpisertib Fosmecarbil | Phase 2 | Ulcerative Colitis | - | - |
Dronedarone | Phase 2 | Atrial Fibrillation | - | - |
tegobuvir capsule | Phase 2 | Chronic Genotype 1a or 1b HCV Infection | - | - |
anitocabtagene-autoleucel | Phase 2 | Multiple Myeloma | - | - |
KTE-X19 | Phase 2 | Relapsed/Refractory Mantle Cell Lymphoma | - | - |
SEL | Phase 2 | Diabetic Kidney Disease | - | - |
MBX-2982 | Phase 2 | Diabetes | - | - |
CILO | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Pegasys® | Phase 2 | Chronic Hepatitis C Infection | - | - |
Levetiracetam | Phase 2 | Refractory Diffuse Large B Cell Lymphoma (DLBCL) | - | - |
Denikitug | Phase 2 | HER2-negative | - | - |
KITE-363 | Phase 2 | Relapsed and/or Refractory B-cell Lymphoma | - | - |
VDV | Phase 2 | Hepatitis C Virus Infection | - | - |
Simtuzumab | Phase 2 | Primary Sclerosing Cholangitis (PSC) | - | - |
FTI, AZLI | Phase 2 | Cystic Fibrosis | - | - |
Tecadenoson | Phase 2 | Atrial Fibrillation | - | - |
OAV Regimen | Phase 2 | Chronic HBV Infection | - | - |
EFV | Phase 2 | Hepatitis C | - | - |
milatuzumab | Phase 2 | Chronic Lymphocytic Lymphoma | - | - |
Emtricitabine | Phase 2 | HIV Infections | - | - |
abacavir 300mg twice daily | Phase 2 | Lipodystrophy | - | - |
Tegobuvir | Phase 2 | Hepatitis C, Chronic | - | - |
GS-9190 | Phase 2 | HCV Infection | - | - |
Brexucabtagene Autoleucel (KTE-X19) | Phase 2 | Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | - | - |
MBX-8025 2 mg Capsule | Phase 2 | Primary Biliary Cirrhosis | - | - |
GS-9450 | Phase 2 | Nonalcoholic Steatohepatitis | - | - |
hA20-humanized anti-CD20 antibody | Phase 2 | Non-Hodgkin's Lymphoma | - | - |
LDV | Phase 2 | Chronic Hepatitis C Infection | - | - |
GS-1427 | Phase 2 | Ulcerative Colitis | - | - |
GS-5806 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
Eleclazine | Phase 2 | Ventricular Arrhythmia | - | - |
GS-5885 | Phase 2 | Hepatitis C, Chronic | - | - |
90Y-hLL2 | Phase 2 | NHL | - | - |
Vesatolimod | Phase 2 | HIV-1-infection | - | - |
Other approved antivirals | Phase 2 | Chronic Hepatitis B | - | - |
Cilofexor | Phase 2 | Primary Sclerosing Cholangitis | - | - |
GS-5885 tablet | Phase 2 | Hepatitis C, Chronic | - | - |
Selonsertib | Phase 2 | Alcoholic Hepatitis (AH) | - | - |
VEL | Phase 2 | Hepatitis C | - | - |
Teropavimab | Phase 2 | HIV Infection | - | - |
hMN14 (labetuzumab) | Phase 2 | Pancreatic Neoplasms | - | - |
EVG | Phase 2 | HIV Infections | - | - |
Abacavir sulfate | Phase 2 | HIV Infections | - | - |
Firsocostat | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
GS-9674 | Phase 2 | Nonalcoholic Steatohepatitis (NASH) | - | - |
Lanraplenib | Phase 2 | Lupus Membranous Nephropathy | - | - |
Presatovir | Phase 2 | Respiratory Syncytial Virus | - | - |
Selgantolimod | Phase 2 | Chronic Hepatitis B | - | - |
GS-9669 | Phase 2 | Chronic HCV Infection | - | - |
Zimberelimab (ZIM) | Phase 2 | Lung Cancer | - | - |
Arhalofenate 600 mg | Phase 2 | Gout | - | - |
GS-9256 | Phase 2 | HCV Infection | - | - |
MBX-2044 | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MBX-8025 50 mg (Dose Escalation Period 1) | Phase 2 | Homozygous Familial Hypercholesterolemia | - | - |
Tirabrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Emtricitabine/tenofovir disoproxil fumarate (F/TDF) | Phase 2 | Pre-Exposure Prophylaxis of HIV Infection | - | - |
Indinavir sulfate | Phase 2 | HIV Infections | - | - |
GS-4321 | Phase 2 | Chronic Hepatitis Delta | - | - |
90Y-hPAM4 | Phase 2 | Pancreatic Cancer | - | - |
Edecesertib | Phase 2 | Cutaneous Lupus Erythematosus (CLE) | - | - |
Triple-Negative Breast Cancer
1 drug in this indication
HIV Prevention
1 drug in this indication
HIV-1
1 drug in this indication
HIV
1 drug in this indication
Myelodysplastic Syndrome
1 drug in this indication
Rheumatoid Arthritis
1 drug in this indication
Hepatitis C, Chronic
1 drug in this indication
Refractory Diffuse Large B Cell Lymphoma
1 drug in this indication
CAR-T cell therapy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Gilead Sciences, Inc.'s drug pipeline?→
CatalystAlert tracks 200 drug candidates in Gilead Sciences, Inc.'s (GILD) pipeline across Phase 3, Phase 2, Approved. Its lead program is MTX (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Gilead Sciences, Inc.'s next FDA catalyst?→
Gilead Sciences, Inc.'s (GILD) next tracked catalyst is a Phase 2 expected August 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track GILD biotech catalysts?→
Add GILD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Gilead Sciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.